-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EPI-004 in Cancer Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EPI-004 in Cancer PainDrug Details:EPI-004 is under development for the treatment of chronic pain from cancer....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EPI-006 in Opium (Opioid) Addiction
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EPI-006 in Opium (Opioid) Addiction Drug Details: EPI-006 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Dronabinol) in Sedation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Cannabidiol + Dronabinol) in Sedation Drug Details:CannEpil, a fixed-dose combination of tetrahydrocannabinol (THC) and cannabinoid (CBD)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APIRx-1602 in Psoriasis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APIRx-1602 in Psoriasis Drug Details: APIRx-1602 (AX-1602) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APIRx-1601 in Vitiligo
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APIRx-1601 in Vitiligo Drug Details: APIRx-1601 is under development for the treatment of skin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EPI-005 in Post-Traumatic Stress Disorder (PTSD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EPI-005 in Post-Traumatic Stress Disorder (PTSD)Drug Details:EPI-005 is under development for the treatment of post-traumatic stress...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Dronabinol) in Epilepsy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Dronabinol) in Epilepsy Drug Details: CannEpil, a fixed-dose combination of tetrahydrocannabinol (THC) and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Cannabidiol + Cannabinol + Tetrahydrocannabinol) in PainDrug Details:Cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabinol (CBN) (Zenivol) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canchew Plus in Irritable Bowel Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canchew Plus in Irritable Bowel Syndrome Drug Details: Canchew Plus is under development for...
-
Product Insights
![]()
CBD Capital – Butterworth Apartment Tower Development – Penang
Equip yourself with the essential tools needed to make informed and profitable decisions with our CBD Capital - Butterworth Apartment Tower Development - Penang report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.